DS
SGTX

David Shaw’s Sigilon Therapeutics, Inc. Common Stock SGTX Stock Holding History

David Shaw’s Portfolio SGTX Stock Details SGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-3,189
Closed -$61K – 5960
2022
Q1 		$61K Sell
3,189
-368
-10% -$8.2K ﹤0.01% 5097
2021
Q4 		$128K Buy
+3,557
New +$202K ﹤0.01% 5008
2021
Q3 		– Sell
-1,111
Closed -$155K – 5381
2021
Q2 		$155K Buy
+1,111
New +$195K ﹤0.01% 4494

Other funds holding SGTX

FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
Canada Pension Plan Investment Board
Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $181B AUM 41.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
HP
Harbourvest Partners Boston, Massachusetts $170M AUM 34.45% 1-Year Est. Return
State of Wisconsin Investment Board
State of Wisconsin Investment Board Madison, Wisconsin $49.6B AUM 39.59% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

David Shaw's SGTX Position: Q2 2022 in Review

David Shaw sold out of Sigilon Therapeutics, Inc. Common Stock (SGTX) in Q2 2022, closing a stake of 3,189 shares — an estimated $61K sold.

David Shaw first reported a position in SGTX in Q2 2021 and held it in 3 quarters. The position peaked at $155K in Q2 2021. 37 funds tracked by Wall St. Rank hold SGTX as of Q2 2022.

  • David Shaw reported no remaining Sigilon Therapeutics, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • David Shaw sold 3,189 Sigilon Therapeutics, Inc. Common Stock shares in Q2 2022, an estimated $61K.
  • David Shaw first reported a position in Sigilon Therapeutics, Inc. Common Stock in Q2 2021 and held it in 3 quarters.
  • David Shaw's Sigilon Therapeutics, Inc. Common Stock position peaked at $155K in Q2 2021.
  • 37 funds tracked by Wall St. Rank held Sigilon Therapeutics, Inc. Common Stock as of Q2 2022.

Based on D.E. Shaw & Co's 13F filing for Q2 2022, filed 15 Aug 2022.